Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 180

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing (January 2021)

Open access
Hanson, Kimberly E, Caliendo, Angela M, Arias, Cesar A, Hayden, Mary K, Englund, Janet A, Lee, Mark J, Loeb, Mark, Patel, Robin, El Alayli, Abdallah, Altayar, Osama, Patel, Payal, Falck-Ytter, Yngve, Lavergne, Valery, Morgan, Rebecca L, Murad, M Hassan, Sultan, Shahnaz, Bhimraj, Adarsh, Mustafa, Reem A · 2024 · Clinical Infectious Diseases

Abstract

Background: Accurate molecular diagnostic tests are necessary for confirming a diagnosis of coronavirus disease 2019 (COVID-19). Direct detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acids in respiratory tract specimens informs patient, healthcare institution and public health level decision-making. The numbers of available SARS-CoV-2 nucleic acid detection tests are rapidly increasing, as is the COVID-19 diagnostic literature. Thus, the Infectious Diseases Society of America (IDSA) recognized a significant need for frequently updated systematic reviews of the literature to inform evidence-based best practice guidance. Objective: The IDSA’s goal was to develop an evidence-based diagnostic guideline to assist clinicians, clinical laboratorians, patients and policymakers in decisions related to the optimal use of SARS-CoV-2 nucleic acid amplification tests. In addition, we provide a conceptual framework for understanding molecular diagnostic test performance, discuss the nuance of test result interpretation in a variety of practice settings and highlight important unmet research needs in the COVID-19 diagnostic testing space. Methods: IDSA convened a multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review to identify and prioritize clinical questions and outcomes related to the use of SARS-CoV-2 molecular diagnostics. Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. Results: The panel agreed on 17 diagnostic recommendations. Conclusions: Universal access to accurate SARS-CoV-2 nucleic acid testing is critical for patient care, hospital infection prevention and the public response to the COVID-19 pandemic. Information on the clinical performance of available tests is rapidly emerging, but the quality of evidence of the current literature is considered moderate to very low. Recognizing these limitations, the IDSA panel weighed available diagnostic evidence and recommends nucleic acid testing for all symptomatic individuals suspected of having COVID-19. In addition, testing is recommended for asymptomatic individuals with known or suspected contact with a COVID-19 case. Testing asymptomatic individuals without known exposure is suggested when the results will impact isolation/quarantine/personal protective equipment (PPE) usage decisions, dictate eligibility for surgery, or inform solid organ or hematopoietic stem cell transplantation timing. Ultimately, prioritization of testing will depend on institutional-specific resources and the needs of different patient populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciab048

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 159

  1. Zhu, 2020, A novel coronavirus from patients with Pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017 · DOI · Paper page
  2. Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 · DOI · Paper page
  3. Gorbalenya, 2020, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol, 5, 536, 10.1038/s41564-020-0695-z · DOI · Paper page
  4. Burke, 2020, Symptom profiles of a convenience sample of patients with COVID-19—United States, January–April 2020, Morb Mortal Wkly Rep, 69, 904, 10.15585/mmwr.mm6928a2 · DOI · Paper page
  5. Morgan, 2018, Development of rapid guidelines: 3. GIN-McMaster guideline development checklist extension for rapid recommendations, Health Res Policy Syst, 16, 63, 10.1186/s12961-018-0330-0 · DOI
  6. Hanson, 2020, Infectious Diseases Society of America Guidelines on the diagnosis of coronavirus disease 2019 (COVID-19): serologic testing, Clin Infect Dis, ciaa1343
  7. Doebler, 2020, mada: meta-analysis of diagnostic accuracy. R package 0.5.10. ed
  8. Team RC, 2020, R: a language and environment for statistical computing
  9. Schünemann, 2020, GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy, J Clin Epidemiol, 122, 129, 10.1016/j.jclinepi.2019.12.020 · DOI · Paper page
  10. Schünemann, 2020, GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables, J Clin Epidemiol, 122, 142, 10.1016/j.jclinepi.2019.12.021 · DOI · Paper page
  11. Ai, 2020, Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China, 10.1101/2020.02.13.20022673 · DOI
  12. Alexander, 2014, World Health Organization recommendations are often strong based on low confidence in effect estimates, J Clin Epidemiol, 67, 629, 10.1016/j.jclinepi.2013.09.020 · DOI
  13. Guyatt, 2016, Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group, J Clin Epidemiol, 80, 3, 10.1016/j.jclinepi.2016.07.006 · DOI · Paper page
  14. Bordi, 2020, Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020, Euro Surveill, 25, 2000170, 10.2807/1560-7917.ES.2020.25.8.2000170 · DOI
  15. Hsih, 2020, Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan, J Microbiol Immunol Infect, 53, 459, 10.1016/j.jmii.2020.03.008 · DOI
  16. Liu, 2020, Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020, Clin Chim Acta, 505, 172, 10.1016/j.cca.2020.03.009 · DOI · Paper page
  17. Tolia, 2020, Preliminary results of initial testing for coronavirus (COVID-19) in the Emergency Department, West J Emerg Med, 21, 503, 10.5811/westjem.2020.3.47348 · doi:10.5811/westjem.2020.3.47348
  18. Pu, 2020, Screening and managing of suspected or confirmed novel coronavirus (COVID-19) patients: experiences from a tertiary hospital outside Hubei province, 10.1101/2020.03.20.20038679 · DOI
  19. Huang, 2020, Triaging patients in the outbreak of the 2019 novel coronavirus, 10.1101/2020.03.13.20035212 · doi:10.1101/2020.03.13.20035212
  20. Azzi, 2020, Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: a diagnostic accuracy study, J Infect, 81, e75, 10.1016/j.jinf.2020.06.042 · DOI
  21. Hanson, 2020, Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2, J Clin Microbiol, 58, e01824-20, 10.1128/JCM.01824-20 · doi:10.1128/jcm.01824-20
  22. Iwasaki, 2020, Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva, J Infect, 81, e145, 10.1016/j.jinf.2020.05.071 · DOI · Paper page
  23. Landry, 2020, Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients, J Clin Virol, 130, 104567, 10.1016/j.jcv.2020.104567 · DOI
  24. Leung, 2021, Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2, J Med Virol, 93, 533, 10.1002/jmv.26258 · doi:10.1002/jmv.26258
  25. McCormick-Baw, 2020, Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using cepheid xpert xpress SARS-CoV-2, J Clin Microbiol, 58, e01109, 10.1128/JCM.01109-20 · DOI
  26. McCulloch, 2020, Comparison of unsupervised home self-collected midnasal swabs with clinician-collected nasopharyngeal swabs for detection of SARS-CoV-2 infection, JAMA Netw Open, 3, e2016382, 10.1001/jamanetworkopen.2020.16382 · DOI · Paper page
  27. Migueres, 2020, Saliva sampling for diagnosing SARS-CoV-2 infections in symptomatic patients and asymptomatic carriers, J Clin Virol, 130, 104580, 10.1016/j.jcv.2020.104580 · doi:10.1016/j.jcv.2020.104580
  28. Otto, 2020, Posterior oropharyngeal salivafor the detection of SARS-CoV-2, Clin Infect Dis, ciaa1181
  29. Patel, 2020, Performance of oropharyngeal swab testing compared to nasopharyngeal swab testing for diagnosis of COVID-19 - United States, January 2020 - February 2020, Clin Infect Dis, 72, 482, 10.1093/cid/ciaa759 · doi:10.1093/cid/ciaa759
  30. Pham, 2020, Performance characteristics of a high-throughput automated transcription-mediated amplification test for SARS-CoV-2 detection, J Clin Microbiol, 58, e01669-20, 10.1128/JCM.01669-20 · doi:10.1128/jcm.01669-20
  31. Procop, 2021, A comparison of five SARS-CoV-2 molecular assays with clinical correlations, Am J Clin Pathol, 155, 69, 10.1093/ajcp/aqaa181 · doi:10.1093/ajcp/aqaa181
  32. Tu, 2020, Swabs collected by patients or health care workers for SARS-CoV-2 testing, N Engl J Med, 383, 494, 10.1056/NEJMc2016321 · DOI · Paper page
  33. Vermeiren, 2020, Comparison of copan ESwab and FLOQSwab for COVID-19 diagnosis: working around a supply shortage, J Clin Microbiol, 58, e00669-20, 10.1128/JCM.00669-20 · doi:10.1128/jcm.00669-20
  34. Wang, 2020, Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously, Int J Infect Dis, 94, 107, 10.1016/j.ijid.2020.04.023 · DOI · Paper page
  35. Williams, 2020, Saliva as a noninvasive specimen for detection of SARS-CoV-2, J Clin Microbiol, 58, e00776-20, 10.1128/JCM.00776-20 · DOI · Paper page
  36. Yokota, 2020, Mass screening of asymptomatic persons for SARS-CoV-2 using saliva, Clin Infect Dis, ciaa1388
  37. LeBlanc, 2020, A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2, J Clin Virol, 128, 104442, 10.1016/j.jcv.2020.104442 · DOI
  38. Pere, 2020, Nasal swab sampling for SARS-CoV-2: a convenient alternative in times of nasopharyngeal swab shortage, J Clin Microbiol, 58, e00721-20, 10.1128/JCM.00721-20 · DOI
  39. Vlek, 2021, Combined throat/nasal swab sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling, Eur J Clin Microbiol Infect Dis, 40, 193, 10.1007/s10096-020-03972-y · doi:10.1007/s10096-020-03972-y
  40. Byrne, 2020, Saliva alternative to upper respiratory swabs for SARS-CoV-2 diagnosis, Emerg Infect Dis, 26, 2770, 10.3201/eid2611.203283 · doi:10.3201/eid2611.203283
  41. Güçlü, 2020, Comparison of saliva and oro-nasopharyngeal swab sample in the molecular diagnosis of COVID-19, Rev Assoc Med Bras (1992), 66, 1116, 10.1590/1806-9282.66.8.1116 · DOI
  42. Lin, 2020, Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19), Clin Chem Lab Med, 58, 1089, 10.1515/cclm-2020-0187 · DOI
  43. Moreno-Contreras, 2020, Saliva sampling and its direct lysis, an excellent option to increase the number of SARS-CoV-2 diagnostic tests in settings with supply shortages, J Clin Microbiol, 58, e01659-20, 10.1128/JCM.01659-20 · DOI
  44. Pasomsub, 2021, Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study, Clin Microbiol Infect, 27, 285.e1, 10.1016/j.cmi.2020.05.001 · DOI · Paper page
  45. Skolimowska, 2020, Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence, Clin Microbiol Infect, 26, 1711, 10.1016/j.cmi.2020.07.015 · DOI
  46. Vaz, 2020, Saliva is a reliable, non-invasive specimen for SARS-CoV-2 detection, Braz J Infect Dis, 24, 422, 10.1016/j.bjid.2020.08.001 · DOI
  47. Wehrhahn, 2020, Self-collection: an appropriate alternative during the SARS-CoV-2 pandemic, J Clin Virol, 128, 104417, 10.1016/j.jcv.2020.104417 · DOI
  48. Tu, 2020, Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs, 10.1101/2020.04.01.20050005 · doi:10.1101/2020.04.01.20050005
  49. Wehrhahn, 2020, Self-collection: an appropriate alternative during the SARS-CoV-2 pandemic, 10.1101/2020.04.09.20057901 · doi:10.1101/2020.04.09.20057901
  50. Kojima, 2020, Self-collected oral fluid and nasal swabs demonstrate comparable sensitivity to clinician collected nasopharyngeal swabs for Covid-19 detection, 10.1101/2020.04.11.20062372 · doi:10.1101/2020.04.11.20062372
  51. Kim, 2020, Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea, J Korean Med Sci, 35, e86, 10.3346/jkms.2020.35.e86 · DOI · Paper page
  52. Yang, 2020, Comparative sensitivity of different respiratory specimen types for molecular diagnosis and monitoring of SARS-CoV-2 shedding, Innovation (N Y), 1, 100061
  53. Gao, 2020, Evaluation the auxiliary diagnosis value of antibodies assays for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19), medRxiv, 10.1101/2020.03.26.20042044 · doi:10.1101/2020.03.26.20042044
  54. Wang, 2020, Detection of SARS-CoV-2 in different types of clinical specimens, JAMA, 323, 1843
  55. Yu, 2020, Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients, Clin Infect Dis, 71, 793, 10.1093/cid/ciaa345 · DOI · Paper page
  56. Tan, 2020, Viral kinetics and antibody responses in patients with COVID-19, medRxiv, 10.1101/2020.03.24.20042382 · DOI · Paper page
  57. Lin, 2020, Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2) infected pneumonia (COVID-19), medRxiv, 10.1101/2020.02.21.20026187 · doi:10.1101/2020.02.21.20026187
  58. Ai, 2020, Analysis of factors associated early diagnosis in coronavirus disease 2019 (COVID-19), 10.1101/2020.04.09.20059352 · DOI
  59. Zhou, 2020, Clinical features and outcomes of 197 adult discharged patients with COVID-19 in Yichang, Hubei, 10.1101/2020.03.26.20041426 · DOI
  60. Bulterys, 2020, Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2, J Clin Virol, 129, 104427, 10.1016/j.jcv.2020.104427 · DOI
  61. Eckel, 2020, Variplex™ test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction, Eur J Clin Microbiol Infect Dis, 39, 2373, 10.1007/s10096-020-03983-9 · doi:10.1007/s10096-020-03983-9
  62. Harrington, 2020, Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients, J Clin Microbiol, 58, 10.1128/JCM.00798-20 · DOI · Paper page
  63. Hogan, 2020, Comparison of the accula SARS-CoV-2 test with a laboratory-developed assay for detection of SARS-CoV-2 RNA in clinical nasopharyngeal specimens, J Clin Microbiol, 58, e01072-20, 10.1128/JCM.01072-20 · DOI
  64. Hou, 2020, Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 assay for the detection of SARS-CoV-2 in oropharyngeal swab specimens, J Clin Microbiol, 58, e01288-20, 10.1128/JCM.01288-20 · DOI
  65. Lieberman, 2020, Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories, J Clin Microbiol, 58, e00821-20, 10.1128/JCM.00821-20 · DOI · Paper page
  66. Liotti, 2020, Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2 molecular detection, Clin Microbiol Infect, 26, 1699, 10.1016/j.cmi.2020.07.026 · DOI
  67. Loeffelholz, 2020, Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 test, J Clin Microbiol, 58, e00926-20, 10.1128/JCM.00926-20 · DOI · Paper page
  68. McDonald, 2020, Diagnostic performance of a rapid point-of-care test for SARS-CoV-2 in an Urban Emergency Department Setting, Acad Emerg Med, 27, 764, 10.1111/acem.14039 · DOI
  69. Mitchell, 2020, Evaluation of the COVID19 ID NOW EUA assay, J Clin Virol, 128, 104429, 10.1016/j.jcv.2020.104429 · DOI
  70. Moore, 2020, Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of SARS-CoV-2, Clin Microbiol, 58, e00938-20, 10.1128/JCM.00938-20 · DOI
  71. Moran, 2020, Detection of SARS-CoV-2 by use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays, J Clin Microbiol, 58, e00772-20, 10.1128/JCM.00772-20 · DOI
  72. Smith, 2020, Analytical and clinical comparison of three nucleic acid amplification tests for SARS-CoV-2 detection, J Clin Microbiol, 58, e01134-20, 10.1128/JCM.01134-20 · doi:10.1128/jcm.01134-20
  73. Smithgall, 2020, Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the rapid detection of SARS-CoV-2, J Clin Virol, 128, 104428, 10.1016/j.jcv.2020.104428 · DOI · Paper page
  74. Stevens, 2020, Comparison of a point-of-care assay and a high-complexity assay for detection of SARS-CoV-2 RNA, J Appl Lab Med, 5, 1307, 10.1093/jalm/jfaa135 · DOI
  75. Thwe, 2020, How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory, Diagn Microbiol Infect Dis, 98, 115123, 10.1016/j.diagmicrobio.2020.115123 · DOI
  76. Visseaux, 2020, Evaluation of the QIAstat-Dx respiratory SARS-CoV-2 panel, the first rapid multiplex PCR commercial assay for SARS-CoV-2 detection, J Clin Microbiol, 58, e00630-20, 10.1128/JCM.00630-20 · DOI
  77. Wolters, 2020, Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic, J Clin Virol, 128, 104426, 10.1016/j.jcv.2020.104426 · DOI
  78. Zhen, 2020, Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2, J Clin Microbiol, 58, e00783-20, 10.1128/JCM.00783-20 · DOI · Paper page
  79. Hu, 2020, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, 10.1101/2020.02.20.20025619 · DOI
  80. Zou, 2020, SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med, 382, 1177, 10.1056/NEJMc2001737 · DOI · Paper page
  81. Danis, 2020, Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020, Clin Infect Dis, 10.1093/cid/ciaa424 · DOI · Paper page
  82. Bi, 2020, Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1286 of their close contacts, 10.1101/2020.03.03.20028423 · DOI
  83. Wei, 2020, Presymptomatic transmission of SARS-CoV-2—Singapore, January 23-March 16, 2020, MMWR Morb Mortal Wkly Rep, 69, 411, 10.15585/mmwr.mm6914e1 · DOI · Paper page
  84. Kimball, 2020, Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020, MMWR Morb Mortal Wkly Rep, 69, 377, 10.15585/mmwr.mm6913e1 · DOI · Paper page
  85. Gostic, 2020, Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19, eLife, 9, e55570, 10.7554/eLife.55570 · DOI · Paper page
  86. Folgueira, 2020, SARS-CoV-2 infection in Health Care Workers in a large public hospital in Madrid, Spain, during March 2020, 10.1101/2020.04.07.20055723 · DOI
  87. Lu, 2020, COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020, Emerg Infect Dis, 26, 1628, 10.3201/eid2607.200764 · DOI · Paper page
  88. Yu, 2020, SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan, 10.1101/2020.02.22.20025320 · doi:10.1101/2020.02.22.20025320
  89. Waghmare, 2020, Guidelines for COVID-19 management in hematopoietic cell transplantation and cellular therapy recipients, Biol Blood Marrow Transplant, 26, 1983, 10.1016/j.bbmt.2020.07.027 · DOI
  90. 2020, Special considerations in solid organ transplant, hematopoietic stem cell transplant, and cellular therapy candidates, donors, and recipients
  91. Ljungman, 2020, The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy, Bone Marrow Transplant, 55, 2071, 10.1038/s41409-020-0919-0 · DOI · Paper page
  92. Abbas, 2017, Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles, Int J Infect Dis, 62, 86, 10.1016/j.ijid.2017.07.011 · doi:10.1016/j.ijid.2017.07.011
  93. Pochon, 2018, Respiratory virus infections in hematopoietic cell transplant recipients, Front Microbiol, 9, 3294, 10.3389/fmicb.2018.03294 · DOI
  94. Gallo, 2020, Cancer population may be paradoxically protected from severe manifestations of COVID-19, J Infect, 81, e156, 10.1016/j.jinf.2020.06.011 · DOI
  95. Li, 2020, Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission, Leukemia, 34, 2384, 10.1038/s41375-020-0986-7 · DOI
  96. Miyashita, 2020, Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City, Ann Oncol, 31, 1088, 10.1016/j.annonc.2020.04.006 · DOI · Paper page
  97. Pinto, 2020, SARS-CoV-2 positive hospitalized cancer patients during the Italian outbreak: the Cohort Study in Reggio Emilia, Biology, 9, 181, 10.3390/biology9080181 · DOI
  98. Sanchez-Pina, 2020, Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies, Eur J Haematol, 105, 597, 10.1111/ejh.13493 · DOI
  99. Shah, 2020, Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience, Br J Haematol, 190, e279, 10.1111/bjh.16935 · DOI
  100. Stroppa, 2020, Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy), Future Oncol, 16, 1425, 10.2217/fon-2020-0369 · DOI
  101. Tian, 2020, Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study, Lancet Oncol, 21, 893, 10.1016/S1470-2045(20)30309-0 · DOI · Paper page
  102. Yigenoglu, 2021, The outcome of COVID-19 in patients with hematological malignancy, J Med Virol, 93, 1099, 10.1002/jmv.26404 · DOI
  103. Aries, 2020, Clinical outcome of coronavirus disease 2019 in haemato-oncology patients, Br J Haematol, 190, e64-e7, 10.1111/bjh.16852 · DOI
  104. Assaad, 2020, High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR, Eur J Cancer, 135, 251, 10.1016/j.ejca.2020.05.028 · DOI
  105. Dufour, 2020, COVID-19, impact on myeloma patients, Ann Hematol, 99, 1947, 10.1007/s00277-020-04147-7 · DOI
  106. Engelhardt, 2020, Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany, Haematologica, 105, 2872, 10.3324/haematol.2020.262758 · DOI
  107. Garassino, 2020, COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, Lancet Oncol, 21, 914, 10.1016/S1470-2045(20)30314-4 · DOI · Paper page
  108. Infante, 2020;, COVID-19 in patients with hematological malignancies: a retrospective case series, Int J Lab Hematol, 10.1111/ijlh.13301 · DOI
  109. Jee, 2020, Chemotherapy and COVID-19 outcomes in patients with cancer, J Clin Oncol, 38, 3538, 10.1200/JCO.20.01307 · DOI · Paper page
  110. Lee, 2020, COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study, Lancet Oncol, 21, 1309, 10.1016/S1470-2045(20)30442-3 · DOI · Paper page
  111. Liang, 2020, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol, 21, 335, 10.1016/S1470-2045(20)30096-6 · DOI · Paper page
  112. Mehta, 2020, Case fatality rate of cancer patients with COVID-19 in a New York Hospital System, Cancer Discov, 10, 935, 10.1158/2159-8290.CD-20-0516 · DOI · Paper page
  113. Passamonti, 2020, Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, Lancet Haematol, 7, e737, 10.1016/S2352-3026(20)30251-9 · DOI · Paper page
  114. Pinato, 2020, Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe, Cancers, 12, 1841, 10.3390/cancers12071841 · DOI
  115. Pinato, 2020, Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients, Cancer Discov, 10, 1465, 10.1158/2159-8290.CD-20-0773 · DOI · Paper page
  116. Robilotti, 2020, Determinants of COVID-19 disease severity in patients with cancer, Nat Med, 26, 1218, 10.1038/s41591-020-0979-0 · DOI · Paper page
  117. Song, 2020, Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China, Infect Dis Poverty, 9, 82, 10.1186/s40249-020-00707-1 · doi:10.1186/s40249-020-00707-1
  118. Yang, 2020, Clinical characteristics and outcomes of cancer patients with COVID-19, J Med Virol, 92, 2067, 10.1002/jmv.25972 · DOI · Paper page
  119. Yarza, 2020, SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death, Eur J Cancer, 135, 242, 10.1016/j.ejca.2020.06.001 · DOI
  120. Zhang, 2020, Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China, Cancer, 126, 4023, 10.1002/cncr.33042 · DOI
  121. Zhang, 2020, Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China, Ann Oncol, 31, 894, 10.1016/j.annonc.2020.03.296 · DOI · Paper page
  122. Treon, 2020, The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients, Blood, 135, 1912, 10.1182/blood.2020006288 · DOI · Paper page
  123. Thibaud, 2020, Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19, Br J Haematol, 190, e73, 10.1111/bjh.16863 · DOI
  124. Montopoli, 2020, Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532), Ann Oncol, 31, 1040, 10.1016/j.annonc.2020.04.479 · DOI · Paper page
  125. Montero, 2020, Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes, Rheumatol Int, 40, 1593, 10.1007/s00296-020-04676-4 · DOI
  126. Pablos, 2020, Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases, Ann Rheum Dis, 79, 1170, 10.1136/annrheumdis-2020-217763 · DOI
  127. Santos, 2020, Determinants of COVID-19 disease severity in patients with underlying rheumatic disease, Clin Rheumatol, 39, 2789, 10.1007/s10067-020-05301-2 · DOI
  128. Scirè, 2020, COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19), Clin Exp Rheumatol, 38, 748
  129. Winthrop, 2021, SARS CoV-2 infection among patients using immunomodulatory therapies, Ann Rheum Dis, 80, 269, 10.1136/annrheumdis-2020-218580 · doi:10.1136/annrheumdis-2020-218580
  130. Zen, 2020, SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients, J Autoimmun, 112, 102502, 10.1016/j.jaut.2020.102502 · doi:10.1016/j.jaut.2020.102502
  131. Zhao, 2020, Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot spot’ versus in US ‘hot spot’: similarities and differences, Ann Rheum Dis, 10.1136/annrheumdis-2020–218183 · doi:10.1136/annrheumdis-2020-218183
  132. Emmi, 2020, SARS-CoV-2 infection among patients with systemic autoimmune diseases, Autoimmun Rev, 19, 102575, 10.1016/j.autrev.2020.102575 · DOI
  133. Fernandez-Ruiz, 2020, Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus, Arthritis Rheumatol, 72, 1971, 10.1002/art.41450 · DOI
  134. Freites Nuñez, 2020, Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases, Ann Rheum Dis, 79, 1393, 10.1136/annrheumdis-2020-217984 · DOI · Paper page
  135. Gartshteyn, 2020, COVID-19 and systemic lupus erythematosus: a case series, Lancet Rheumatol, 2, e452, 10.1016/S2665-9913(20)30161-2 · doi:10.1016/s2665-9913(20)30161-2
  136. Kumar, 2020, COVID-19 in rheumatic diseases: a random cross-sectional telephonic survey, medRxiv, 10.1101/2020.08.09.20170985 · DOI
  137. Huang, 2020, Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study, Ann Rheum Dis, 79, 1163, 10.1136/annrheumdis-2020-217425 · doi:10.1136/annrheumdis-2020-217425
  138. D’Silva, 2020, Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’, Ann Rheum Dis, 79, 1156, 10.1136/annrheumdis-2020-217888 · DOI · Paper page
  139. Queiro Silva, 2020, COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain, Dermatol Ther, 33, e13961, 10.1111/dth.13961 · doi:10.1111/dth.13961
  140. Strippoli, 2020, Biologic agents in psoriasis: our experience during coronavirus infection, Int J Dermatol, 59, e266, 10.1111/ijd.15002 · DOI
  141. Fougerousse, 2020, Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19, J Eur Acad Dermatol Venereol, 34, e676, 10.1111/jdv.16761 · doi:10.1111/jdv.16761
  142. Gisondi, 2020, The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience, Br J Dermatol, 183, 373, 10.1111/bjd.19158 · doi:10.1111/bjd.19158
  143. Damiani, 2020, Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration, Dermatol Ther, 33, e13475, 10.1111/dth.13475 · doi:10.1111/dth.13475
  144. Parrotta, 2020, COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center, Neurol Neuroimmunol Neuroinflamm, 7, e835, 10.1212/NXI.0000000000000835 · DOI
  145. Fan, 2020, Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders, Neurol Neuroimmunol Neuroinflamm, 7, e787, 10.1212/NXI.0000000000000787 · DOI
  146. Norsa, 2020, Uneventful course in patients with inflammatory bowel disease during the severe acute respiratory syndrome coronavirus 2 outbreak in Northern Italy, Gastroenterology, 159, 371, 10.1053/j.gastro.2020.03.062 · DOI
  147. Scaldaferri, 2020, Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian inflammatory bowel disease centre, United European Gastroenterol J, 8, 775, 10.1177/2050640620929133 · doi:10.1177/2050640620929133
  148. Allocca, 2020, Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the nancy and milan cohorts, Clin Gastroenterol Hepatol, 18, 2134, 10.1016/j.cgh.2020.04.071 · DOI
  149. Rodríguez-Lago, 2020, Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain), Gastroenterology, 159, 781, 10.1053/j.gastro.2020.04.043 · DOI
  150. Taxonera, 2020, 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases, Aliment Pharmacol Ther, 52, 276, 10.1111/apt.15804 · DOI · Paper page
  151. Gubatan, 2020, SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California, Gastroenterology, 159, 1141, 10.1053/j.gastro.2020.05.009 · DOI
  152. Bezzio, 2020, Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study, Gut, 69, 1213, 10.1136/gutjnl-2020-321411 · DOI · Paper page
  153. Khan, 2020, Impact of anti-tumor necrosis factor and thiopurine medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide veterans administration cohort study, Gastroenterology, 159, 1545, 10.1053/j.gastro.2020.05.065 · DOI
  154. Marafini, 2020, Low frequency of COVID-19 in inflammatory bowel diseases, Dig Liver Dis, 52, 1234, 10.1016/j.dld.2020.06.007 · doi:10.1016/j.dld.2020.06.007
  155. Lukin, 2020, Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease, Gastroenterology, 159, 1541, 10.1053/j.gastro.2020.05.066 · DOI
  156. Maus, 2020, Infections associated with the new ‘nibs and mabs’ and cellular therapies, Curr Opin Infect Dis, 33, 281, 10.1097/QCO.0000000000000656 · DOI
  157. Lei, 2020, Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection, EClinicalMedicine, 21, 100331, 10.1016/j.eclinm.2020.100331 · DOI · Paper page
  158. Winichakoon, 2020, Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19, J Clin Microbiol, 58, e00297-20, 10.1128/JCM.00297-20 · DOI · Paper page
  159. Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 · DOI · Paper page

Cited by

See all 180

Metadata

Authors
Hanson, K. E., Caliendo, A. M., Arias, C. A., Hayden, M. K., Englund, J. A., Lee, M. J., Loeb, M., Patel, R., El Alayli, A., Altayar, O., Patel, P., Falck-Ytter, Y., Lavergne, V., Morgan, R. L., Murad, M. H., Sultan, S., Bhimraj, A., & Mustafa, R. A.
Venue
Clinical Infectious Diseases
Published
2021-01-22
Volume
78
Issue
7
Pages
e170-e207
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3122661585
Cited by
180
References
16
FWCI
12.66
Type
journal article
Language
en
Open access
bronze
Funders
Centers for Disease Control and Prevention (6 NU50CK000477-04-01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.